PAPER Béland M, Roucou X
SEARCH RESULTS
331209 RESULTS
PAPER Gerschütz A, Heinsen H, Grünblatt E, Wagner AK, Bartl J, Meissner C, Fallgatter AJ, Al-Sarraj S, Troakes C, Ferrer I, Arzberger T, Deckert J, Riederer P, Fischer M, Tatschner T, Monoranu CM
Neuron-specific alterations in signal transduction pathways associated with Alzheimer's disease.
J Alzheimers Dis. 2014;40(1):135-42. PubMed: 24334724PAPER Rembach A, Watt AD, Wilson WJ, Villemagne VL, Burnham SC, Ellis KA, Maruff P, Ames D, Rowe CC, Macaulay SL, Bush AI, Martins RN, Masters CL, Doecke JD, AIBL Research Group
Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden.
J Alzheimers Dis. 2014;40(1):95-104. PubMed: 24334723PAPER Feld M, Krawczyk MC, Sol Fustiñana M, Blake MG, Baratti CM, Romano A, Boccia MM
Decrease of ERK/MAPK overactivation in prefrontal cortex reverses early memory deficit in a mouse model of Alzheimer's disease.
J Alzheimers Dis. 2014;40(1):69-82. PubMed: 24334722PAPER Pláteník J, Fišar Z, Buchal R, Jirák R, Kitzlerová E, Zvěřová M, Raboch J
GSK3β, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression.
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Apr 3;50:83-93. Epub 2013 Dec 12 PubMed: 24334212PAPER Forest A, Barrou Z, Verny M
[Neurosyphilis and cognitive disorders].
Geriatr Psychol Neuropsychiatr Vieil. 2013 Dec;11(4):423-31. PubMed: 24333822PAPER Delphin-Combe F, Martin-Gaujard G, Roubaud C, Fortin ME, Husson F, Rouch I, Krolak-Salmon P
[Experience of a care pathway for psychological and behavioral symptoms of dementia].
Geriatr Psychol Neuropsychiatr Vieil. 2013 Dec;11(4):416-22. PubMed: 24333821PAPER Bana L, Minniti S, Salvati E, Sesana S, Zambelli V, Cagnotto A, Orlando A, Cazzaniga E, Zwart R, Scheper W, Masserini M, Re F
Liposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect Aβ aggregation features and cross the blood-brain-barrier: Implications for therapy of Alzheimer disease.
Nanomedicine. 2013 Dec 10; PubMed: 24333591PAPER Kim BH, Lyubchenko YL
Nanoprobing of misfolding and interactions of amyloid β 42 protein.
Nanomedicine. 2014 May;10(4):871-8. Epub 2013 Dec 10 PubMed: 24333588PAPER Marksteiner J, Imarhiagbe D, Defrancesco M, Deisenhammer EA, Kemmler G, Humpel C
Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: a pilot-study.
Exp Gerontol. 2014 Feb;50:114-21. Epub 2013 Dec 10 PubMed: 24333505PAPER Alagiakrishnan K, Sankaralingam S, Ghosh M, Mereu L, Senior P
Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease.
Discov Med. 2013 Dec;16(90):277-86. PubMed: 24333407PAPER Michael R, Otto C, Lenferink A, Gelpi E, Montenegro GA, Rosandić J, Tresserra F, Barraquer RI, Vrensen GF
Absence of amyloid-beta in lenses of Alzheimer patients: a confocal Raman microspectroscopic study.
Exp Eye Res. 2014 Feb;119:44-53. Epub 2013 Dec 12 PubMed: 24333259PAPER Cochran JN, Hall AM, Roberson ED
The dendritic hypothesis for Alzheimer's disease pathophysiology.
Brain Res Bull. 2014 Apr;103:18-28. Epub 2013 Dec 12 PubMed: 24333192PAPER Lee DR, McKeith I, Mosimann U, Ghosh-Nodial A, Grayson L, Wilson B, Thomas AJ
The Dementia Cognitive Fluctuation Scale, a New Psychometric Test for Clinicians to Identify Cognitive Fluctuations in People with Dementia.
Am J Geriatr Psychiatry. 2013 Dec 12; PubMed: 24332982PAPER Hong YJ, Yoon B, Shim YS, Han IW, Han SH, Park KH, Choi SH, Ku BD, Yang DW
Do Alzheimer's disease (AD) and subcortical ischemic vascular dementia (SIVD) progress differently?
Arch Gerontol Geriatr. 2014 May-Jun;58(3):415-9. Epub 2013 Nov 22 PubMed: 24332770Current Filters
No filters selected